256 related articles for article (PubMed ID: 20169138)
1. Angiogenesis inhibition in prostate cancer: current uses and future promises.
Aragon-Ching JB; Madan RA; Dahut WL
J Oncol; 2010; 2010():361836. PubMed ID: 20169138
[TBL] [Abstract][Full Text] [Related]
2. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
4. Challenges facing antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies.
Mahdi A; Darvishi B; Majidzadeh-A K; Salehi M; Farahmand L
J Cell Physiol; 2019 May; 234(5):5655-5663. PubMed ID: 30515806
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibitors in the treatment of prostate cancer.
Kluetz PG; Figg WD; Dahut WL
Expert Opin Pharmacother; 2010 Feb; 11(2):233-47. PubMed ID: 20088745
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic agents in cancer therapy.
Lenz HJ
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and prostate cancer: important laboratory and clinical findings.
Cox MC; Permenter M; Figg WD
Curr Oncol Rep; 2005 May; 7(3):215-9. PubMed ID: 15847713
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
Bender RJ; Mac Gabhann F
BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
10. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
Raben D; Helfrich B
Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis Inhibition in Prostate Cancer: An Update.
Sarkar C; Goswami S; Basu S; Chakroborty D
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32842503
[TBL] [Abstract][Full Text] [Related]
13. MET and VEGF: synergistic targets in castration-resistant prostate cancer.
Aftab DT; McDonald DM
Clin Transl Oncol; 2011 Oct; 13(10):703-9. PubMed ID: 21975330
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
15. The role of angiogenesis inhibitors in prostate cancer.
Aragon-Ching JB; Dahut WL
Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
[TBL] [Abstract][Full Text] [Related]
16. [Application of bevacizumab on metastatic breast cancer].
Guo Yt; Ding L; Li Th
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):708-14. PubMed ID: 23073579
[TBL] [Abstract][Full Text] [Related]
17. Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies.
Zhang Y; Popel AS; Bazzazi H
ACS Pharmacol Transl Sci; 2023 May; 6(5):710-726. PubMed ID: 37200806
[TBL] [Abstract][Full Text] [Related]
18. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
19. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
Schweizer MT; Carducci MA
Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
